We are live on ! Find out more
Bellevue Group

Bellevue Group Portfolio holdings

AUM $4.75B Turnover 23.84%
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+1.11%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.2B
AUM Growth
-$1.07B
Cap. Flow
-$834M
Cap. Flow %
-19.85%
Top 10 Hldgs %
41.95%
Holding
195
New
19
Increased
34
Reduced
87
Closed
40
Avg Time Held
3.8 years
Top 10 Avg Time Held
2.6 years
Top 20 Avg Time Held
2.5 years

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$203M
2
GILD icon
Gilead Sciences
GILD
+$156M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$146M
4
AMGN icon
Amgen
AMGN
+$98.7M
5
VRDN icon
Viridian Therapeutics
VRDN
+$70.3M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$350M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$235M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$225M
4
RNAM
Avidity Biosciences
RNAM
+$190M
5
FOLD icon
Amicus Therapeutics
FOLD
+$153M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Energy 0.07%
3 Technology 0.06%
4 Miscellaneous 0.05%
5 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
COO icon
51
Cooper Companies
COO
$10.9B
$19.5M 0.46%
272,184
-19,775
-7% -$1.56M
2016 Q1
40 quarters
MCK icon
52
McKesson
MCK
$116B
$19.3M 0.46%
22,352
-2,746
-11% -$2.45M
2016 Q1
40 quarters
BDX icon
53
Becton Dickinson
BDX
$52.8B
$19.2M 0.46%
121,887
-143,775
-54% -$26.4M
2016 Q1
40 quarters
HCA icon
54
HCA Healthcare
HCA
$101B
$17.9M 0.43%
37,765
-6,141
-14% -$3.09M
2016 Q1
40 quarters
GKOS icon
55
Glaukos
GKOS
$9.77B
$15.7M 0.37%
145,703
-116,232
-44% -$13.1M
2024 Q1
8 quarters
ELV icon
56
Elevance Health
ELV
$92.9B
$15.4M 0.37%
52,518
-17,127
-25% -$5.63M
2016 Q1
40 quarters
ZBH icon
57
Zimmer Biomet
ZBH
$18B
$14.1M 0.33%
155,571
-83,109
-35% -$7.63M
2016 Q1
40 quarters
PRCT icon
58
Procept Biorobotics
PRCT
$1.04B
$12.6M 0.3%
502,286
-13,144
-3% -$370K
2021 Q3
18 quarters
LIVN icon
59
LivaNova
LIVN
$4.32B
$11.8M 0.28%
+186,185
New +$12M
2026 Q1
0 quarters
HUM icon
60
Humana
HUM
$51.9B
$11.2M 0.27%
64,498
-8,583
-12% -$1.76M
2016 Q1
40 quarters
TMDX icon
61
Transmedics
TMDX
$2.65B
$10.1M 0.24%
101,139
+3,254
+3% +$424K
2020 Q2
23 quarters
VEEV icon
62
Veeva Systems
VEEV
$50.7B
$9.93M 0.24%
56,517
-24,012
-30% -$4.72M
2018 Q2
31 quarters
CNC icon
63
Centene
CNC
$34.8B
$8.55M 0.2%
261,066
-12,608
-5% -$517K
2016 Q1
40 quarters
TEVA icon
64
Teva Pharmaceutical Industries Limited
TEVA
$47.9B
$7.53M 0.18%
250,082
-77,781
-24% -$2.5M
2024 Q1
8 quarters
THC icon
65
Tenet Healthcare
THC
$22.2B
$7.22M 0.17%
38,269
-1,970
-5% -$415K
2025 Q3
2 quarters
TXG icon
66
10x Genomics
TXG
$9.43B
$7M 0.17%
329,492
+7,432
+2% +$149K
2019 Q3
26 quarters
CVS icon
67
CVS Health
CVS
$118B
$6.42M 0.15%
89,363
-19,695
-18% -$1.52M
2016 Q1
40 quarters
NTRA icon
68
Natera
NTRA
$58.3B
$6.34M 0.15%
31,694
-24,342
-43% -$5.24M
2022 Q4
13 quarters
WAY icon
69
Waystar Holding Corp
WAY
$5.41B
$6.18M 0.15%
256,139
+14,405
+6% +$382K
2024 Q2
7 quarters
MDLN icon
70
Medline Inc
MDLN
$32.1B
$6.08M 0.14%
136,635
+18,915
+16% +$835K
2025 Q4
1 quarter
INSP icon
71
Inspire Medical Systems
INSP
$2.03B
$5.14M 0.12%
99,735
-1,026
-1% -$71.8K
2018 Q2
31 quarters
PRVA icon
72
Privia Health
PRVA
$2.89B
$4.66M 0.11%
226,703
-221,460
-49% -$4.99M
2021 Q2
19 quarters
PEN icon
73
Penumbra
PEN
$12.7B
$4.03M 0.1%
12,267
-123,128
-91% -$41.7M
2016 Q1
40 quarters
RNA icon
74
Atrium Therapeutics
RNA
$134M
$3.52M 0.08%
+263,096
New +$3.7M
2026 Q1
0 quarters
PFE icon
75
Pfizer
PFE
$168B
$3.02M 0.07%
107,635
+50,788
+89% +$1.35M
2023 Q3
10 quarters
1 2
3
4 5

Similar funds

Stockbridge Partners
Stockbridge Partners Boston, Massachusetts $4.75B AUM 18.52% 1-Year Est. Return
GTS Securities
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
SONA Asset Management (US)
SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return
Local Pensions Partnership Investment
Local Pensions Partnership Investment London, United Kingdom $4.77B AUM 20.5% 1-Year Est. Return
Nicholas Hoffman & Company
Nicholas Hoffman & Company Atlanta, Georgia $4.74B AUM 18.12% 1-Year Est. Return
PTC
Provident Trust Company Waukesha, Wisconsin $4.77B AUM 29.31% 1-Year Est. Return
Kornitzer Capital Management
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Truepoint Inc
Truepoint Inc Cincinnati, Ohio $4.79B AUM 16.42% 1-Year Est. Return

Bellevue Group's Q1 2026 Portfolio in Review

As of Q1 2026, Bellevue Group held 195 positions worth $4.2B, down 20% from $5.28B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group withdrew a net $834M in Q1 2026, closing 40 positions and reducing 87 holdings. Its most notable exit was Avidity Biosciences, an estimated $190M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Energy and Technology.

Against the trend, Bellevue Group opened a new position in Vaxcyte worth $69.2M.

  • Bellevue Group's largest Q1 2026 buy was Vaxcyte: 1,190,697 shares worth $69.2M.
  • Bellevue Group added most to Regeneron Pharmaceuticals in Q1 2026, an estimated $203M increase.
  • Bellevue Group's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $350M.
  • Bellevue Group fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
  • Bellevue Group's ten largest holdings make up 42% of its $4.2B portfolio in Q1 2026.
  • Bellevue Group opened 19 new positions and closed 40 in Q1 2026.
  • Bellevue Group's portfolio value fell 20% quarter-over-quarter to $4.2B.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.